IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.

Carlo PalmieriRob C SteinXinxue LiuEmma HudsonHanna NicholasHironobu SasanoFouzia GuestiniChris HolcombeSophie BarrettLaura KennySadie ReedAdrian LimLarry HaywardSacha HowellR Charles Coombesnull null

Published in: Breast cancer research and treatment (2017)

The addition of Irosustat to aromatase inhibitor therapy resulted in clinical benefit with an acceptable safety profile. The study met its pre-defined success criterion by both local and central radiological assessments.

Keyphrases

phase ii study
randomized controlled trial
squamous cell carcinoma
open label
stem cells
clinical trial
radiation therapy
mesenchymal stem cells
bone marrow
tyrosine kinase
rectal cancer
endoplasmic reticulum